Lessons Learned from the Application of the HEcoPerMed Guidance to Three Modeling Case Studies
Authors:
- Balázs NagyBNBalázs Nagy
- Tamás ZeleiTZTamás Zelei
- Heleen VellekoopHVHeleen Vellekoop
- Simone HuygensSHSimone Huygens
- Matthijs VersteeghMVMatthijs Versteegh
- Maureen Rutten-Van MölkenMMMaureen Rutten-Van Mölken
- Rositsa Koleva-KolarovaRKRositsa Koleva-Kolarova
- Apostolos TsiachristasATApostolos Tsiachristas
- Sarah WordsworthSWSarah Wordsworth
- László SzilberhornLSLászló Szilberhorn
Open Access
- 1 July 2023
- journal article
- research article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 401-411
Abstract
Background: The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. Materials & methods: In three thera...Keywords
Funding Information
- Horizon 2020 Framework Programme (824997)
This publication has 12 references indexed in Scilit:
- Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UKPersonalized Medicine, 2023
- Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countriesPersonalized Medicine, 2023
- Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy EntrectinibValue in Health, 2022
- Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsBMC Cancer, 2022
- Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised MedicinePharmacoEconomics, 2021
- ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE studyCancer Medicine, 2019
- Economic evaluation of personalized medicine: a call for real-world dataThe European Journal of Health Economics, 2017
- Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 statusCancer, 2013
- The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetesDiabetologia, 2012
- Islet autoantibodies can discriminate maturity‐onset diabetes of the young (MODY) from Type 1 diabetesDiabetic Medicine, 2011